Recombinant antibody fusion proteins for cancer immunotherapy

Current Topics in Microbiology and Immunology

Volumn 213 III, Issue , 1996, Pages 26-53

  Reisfeld, R A ^a   Gillies, S D ^b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Fuji ImmunoPharmaceuticals Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HYBRID PROTEIN; RECOMBINANT ANTIBODY; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DRUG TARGETING; HUMAN; METASTASIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CYTOKINES; EPIDERMAL GROWTH FACTOR; HUMANS; IMMUNOCONJUGATES; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; LYMPHOTOXIN-ALPHA; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEUROBLASTOMA; RECOMBINANT FUSION PROTEINS; SUPERANTIGENS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0030007734     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-80071-9_3     Document Type: Article

References (62)

1. Ashkenazi A, Capon DI, Ward RHR (1993) Immunoadhesins. Int Rev Immunol 10. 219-227
2. Barker E, Mueller BM, Handgretinger R, Herter M, Yu AL, Reisfeld RA (1991) Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res 51: 144-149
3. Brinkmann U, Pastan I (1994) Immunotoxins against cancer. Biochim Biophys Acta 1198. 27-45
4. Bruchelt G, Handgretinger R, Kimmig A, Goeke B, Siedner R, Reisfeld RA, Niethammer D, Treuner J (1989) Effects of granulocytes on human neuroblastoma cells measured by chemiluminescence and chromium-51 release assay J Biolumin Chemolumin 3: 93-103
5. Burke F, Naylor NS, Davies B, Balkwill F (1993) The cytokine wall chart. Immunol Today 14: 165-170
6. Colcher D, Bird R, Roselli M, Hardman KD, Johnson S, Pope S, Dodd S, Pantoliano MW, Milenic DE, Schlom J (1990) in vivo tumor targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst 82 1191-1197
7. Colombo MP, Forni G (1994) Cytokine gene transfer in tumor inhibition and tumor therapy. where are we now? Immunol Today 15: 48-51
8. Dohlsten M, Abrahmsen L, Björk P, Lando PA, Hedlund G, Forsberg G, Brodin T, Gascoigne NRJ, Förberg C, Lind P, Kalland T (1994) Monoclonal antibody super antigen fusion proteins. tumor-specific agents for T cell based tumor therapy. Proc Natl Acad Sci USA 91. 8945-8949
9. Dorai H, McCartney JE, Hudziak RM, Tai M-S, Laminet AA, Houston LL, Huston JS, Oppermann H (1994) Mammalian cell expression of single-chain Fv (sFv) antibody proteins and their C-terminal fusions with interleukin-2 and other effector domains Biotechnology 12: 890-897
10. Favort MC, Floret D, Negrier S, Cochat P, Bouffet E, Dacheng Z, Franks CR, Bijman T, Brunat-Mentigny M, Philip I, Philip T (1989) Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantation. Bone Marrow Transplant 4. 499-504
11. Fell HP, Gayle MA, Grossmaire L, Ledbetter JA (1991) Genetic construction and characterization of a fusion protein consisting of a chimeric F (ab′) with specificity for carcinomas and human IL2. J Immunol 146: 2446-2452
12. Feng GS, Gray PW, Shepard HM, Taylor MW (1988) Antiproliferative activity of a hybrid protein between interferon-γ and tumor necrosis factor-β. Science 241: 1501-1503
13. Gillies SD, Wesolowski JS (1990) Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities. Hum Antibody Hybridomas 1: 47-54
14. Gillies SD, Lo K-M, Wesolowski JS (1989) High-level expression of chimeric antibodies using adapted cDNA variable region cassettes. J Immunol Methods 125: 191-202
15. Gillies SD, Wesolowski JS, Lo K-M (1991a) Targeting human cytotoxic T lymphocytes to kill heterologous epidermal growth factor receptor-bearing cells. J Immunol 146: 1067-1071
16. Gillies SD, Young D, Lo K-M, Foley SF, Reisfeld RA (1991b) Expression of genetically engineered immunoconjugates of lymphotoxin and a chimeric anti-ganglioside GD2 antibody. Hybridoma 3: 347-356
17. Gillies SD, Reilly EB, Lo K-M, Reisfeld RA (1992) Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc Natl Acad Sci USA 89: 1428-1432
18. Gillies SD, Young D, Lo K-M, Roberts S (1993) Biological activity and in vivo clearance of anti-tumor antibody/cytokine fusion proteins. Bioconjugate Chem 4: 230-235
19. Goeddel DV, Aggarwal DD, Gray PW, Leung DW, Nedwin GE, Palladino MA, Patton JS, Pennica D, Shepard HM, Sugarman BJ, Wong GH (1986) Tumor necrosis factors: gene structure and biological activities. Cold Spring Harbor Symp Quant Biol 51: 597-609
20. Grell M, Zimmermann G, Hülser D, Pfizenmayer K, Schewrich P (1994) TNF receptors TR60 and TR80 can mediate apoptosis via induction of distinct signal pathways. J Immunol 153 1963-1972
21. Handgretinger R, Baader P, Dopfer R, Klingbiel T, Reuland P, Reisfeld RA, Treuner J, Niethammer D (1992) A phase I study of neuroblastoma with the anti-ganglioside GD2 study of neuroblastoma with the anti-ganglioside GD2 antibody 14. G2a Cancer Immunol Immunother 35: 199-204
22. Handgretinger R, Anderson K, Lang P, Dopfer R, Klingbiel T, Schrappe M, Reuland P, Gillies SD, Reisfeld RA, Niethammer D (1995) A phase I study of human/mouse chimeric anti-ganglioside GD2 antibody ch14 18 in patients with neuroblastoma. Eur J Cancer 31A: 261-267
23. Hank JA, Robinson RR, Surfus J, Mueller BM, Reisfeld RA, Cheung NK, Sondel PM (1990) Augmentation of antibody-dependent cell mediated cytotoxicity following in vivo therapy with interleukin 2. Cancer Res 50: 5234-5239
24. Hank JA, Surfus J, Gan F, Chew T-L, Hong R, Tans K, Reisfeld RA, Seeger RC, Reynolds CP, Bauer M, Wiersma S, Hammond D, Sondel PM (1994) Treatment of neuroblastoma patients with anti-ganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. J Immunother 15: 29-37
25. Havell EA, Fiers W, North JR (1988) The anti-tumor function of tumor necrosis factor (TNF). J Exp Med 167: 1067-1085
26. Holmes WE, Sliwkowski MX, Akita RW, Henzel WJ, Goeddel DV, Vandlen RL (1992) Identification of heregulin, a specific activator of p185erb2. Science 256: 1205-1210
27. Hoogenboom HR, Raus JC, Volckaert G (1991) Targeting of tumor necrosis factor to tumor cells: secretion by myeloma cells of a genetically engineered antibody-tumor necrosis factor hybrid molecule. Biochim Biophys Acta 1096: 345-354
28. Jung G, Honsik CJ, Reisfeld RA, Muller-Eberhard HJ (1986) Activaton of human peripheral blood mononuclear cells by anti-T3: killing of tumor target cells coated with anti-target-anti-T3 conjugates Proc Natl Acad Sci USA 83: 4479-4483
29. Lewis M, Tarhaglia GA, Lee A, Bennett GL, Rice GC, Wang GHW, Chen EY, Goeddel DV (1991) cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species-specific Proc Natl Acad Sci USA 88. 2830-2834
30. Liu MA, Kranz DM, Kurnick JT, Boyle LA, Levy R, Eisen HN (1985) Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes. Proc Natl Acad Sci USA 82: 8648-8652
31. Liu MA, Nussbaum SR, Eisen HN (1988) Hormone conjugated with antibody to CD3 mediates cytotoxic T-cell lysis of human melanoma cells. Science 239. 395-398
32. Loetscher H, Pan YC, Lahn HW, Gentz R, Kufe DW (1990) Molecular cloning and expression of the human 55 kDa tumor necrosis factor receptor Cell 61: 351-359
33. Moonen P, Mermod J-J, Ernst JF, Herschi M, DeLemarter JF (1987) Increased biological activity of deglycosylated recombinant human granulocyte/macrophage colony-stimulating factor produced by yeast animal cells. Proc Natl Acad Sci USA 84. 4428-4433
34. Mueller BM, Reisfeld RA, Gillies SD (1990) Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2. Proc Natl Acad Sci USA 87. 5702-5705
35. Mujoo K, Cheresh DA, Yang HM, Reisfeld RA (1987) Disialoganglioside GD2 on human neuroblastoma: target antigen for monoclonal antibody mediated cytolysis and suppression of tumor growth Cancer Res 47: 1098-1104
36. Mujoo K, Kipps TJ, Yang HM, Cheresh DA, Wargalla U, Sander DJ, Reisfeld RA (1989) Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal anti-ganglioside GD2 antibody 14.18. Cancer Res 49: 2857-2861
37. Murray JL, Cunningham JE, Brewer H, Mujoo K, Zukiwski AA, Podoloff DA, Kasi LP, Bhadkamkar V, Fritsche HA, Benjamin RS, Legha SS, Ater JL, Jaffe N, Itoh K, Ross MI, Bucana CD, Thompson L, Cheung L, Rosenblum MG (1994) Phase I trial of murine monoclonal antibody 14.G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 12. 184-193
38. Naramura M, Gillies SD, Mendelsohn J, Reisfeld RA, Mueller BM (1994) Mechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL2 fusion protein against human melanoma cells. Immunol Lett 39. 91-99
39. Pai LH, Pastan I (1994) Immunotoxins and recombinant toxins for cancer treatment In: De Vita VT, Hellman S, Rosenberg SA (eds) Important advances in oncology Lippincott, Philadelphia, pp 3-19
40. Pardoll DM (1993) Cancer vaccines. Immunol Today 14: 310-316
41. Reisfeld RA (1992) Potential of genetically engineered monoclonal antibodies for cancer therapy. Pigment Cell Res Suppl 2: 109-112
42. Reisfeld RA, Cheresh DA (1987) Human tumor antigens. In: Dixon FJ (ed) Advances in immunology, vol 40. Academic, New York, pp 323-377.
43. Riethmüller G, Schneider-Gädicke E, Schlimok G, Schmiegel W, Raab R, Höffken G, Gruber R, Pichlmaier H, Hirche H, Pichelmair R (1994) Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 343: 1172-1183
44. Rosenberg SA (1988) Immunotherapy of cancer using interleukin-2: current status and future prospects. Immunol Today 9: 58-62
45. Rosenberg SA (1992) The immunotherapy and gene therapy of cancer J Clin Oncol 10. 180-199
46. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE (1989) Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210: 474-485
47. Rosenberg SA, Yanneli JR, Yang JC, Topalian SL, Schwartzentraber DS, Weber JS, Parkinson DR, Seipp CA, Einhorn JD, White DE (1994) Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2. J Natl Cancer Inst 86: 1159-1166
48. Sabzevari H, Gillies SD, Mueller BM, Pancook JD, Reisfeld RA (1994) A recombinant antibody interleukin-2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc Natl Acad Sci USA 91: 9626-9630
49. Saleh MN, Khazaeli MB, Wheeler RH, Dropcho E, Liu T, Urist M, Miller DM, Lawson S, Dixon P, Russell CH, LoBuglio AF (1992) Phase I trial of the murine monoclonal anti-GD2 antibody 14 G2a in metastatic melanoma. Cancer Res 52. 4342-4347
50. Savage P, So A, Spooner RA, Epenetos AA (1993) A recombinant single chain antibody interleukin-2 fusion protein Br J Cancer 67: 304-310
51. Schall TJ, Lewis M, Koller KJ, Rice GC, Wong GH, Goeddel DV (1990) Molecular cloning and expression of a receptor for human tumor necrosis factor Cell 61 361-370
52. Scherer MT, Ignatowicz L, Winslow G, Kappler J, Marrack P (1993) Superantigens. bacterial and viral proteins that manipulate the immune system Annu Rev Cell Biol 9: 101-128
53. Schlom J (1995) Monoclonal antibodies in cancer therapy. In. De Vita VT, Hellman S, Rosenberg SA (eds) Biologic therapy of cancer, 2nd edn. Lippincott, Philadelphia, pp 507-521
54. Schlom J, Milenic DE, Roselli M, Colcher D, Bird R, Johnson S, Hardman KD, Guadagui F, Greiner JW (1991) New concepts in monoclonal antibody based radioimmuno-diagnosis and radioimmunotherapy of carcinoma Nucl Med Biol 18: 425-435
55. Smith RIF, Morrison SL (1994) Recombinant polymeric IgG an approach to engineering more potent antibodies. Biotechnology 12: 683-688
56. Takahashi H, Nakada T, Puisieus I (1993) Inhibition of human colon cancer growth by antibody-directed human LAK cells in SCID mice. Science 259: 1460-1463
57. Tao M-H, Levy R (1993) Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362: 755-758
58. Tepper RI, Pattengale PK, Leder P (1989) Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57. 503-510
59. Weil-Hillman G, Schell K, Segal DM, Hank JA, Sosman JA, Sondel PM (1991) Activation of human T cells obtained pre- and post-interleukin-2 (IL2) therapy by anti-CD3 monoclonal antibody plus IL2: implications for combined in vivo treatment J Immunother 10: 267-277
60. Winter G, Milstein C (1991) Man-made antibodies Nature 349. 293-299
61. Wright A, Shin S-U, Morrison SL (1992) Genetically engineered antibodies: progress and prospects. Crit Rev Immunol 12: 125-168
62. Yokota T, Milenic DE, Whitlow M, Schlom J (1992) Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 52: 3402-3408